Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallgeir Rui

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Breast Cancer Research and Treatment|July 17, 2023
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapyLubna N Chaudhary, Julie M Jorns, Yunguang Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failureAmy R Peck, Agnieszka K Witkiewicz, Chengbao Liu, et al.
Breast Cancer Research : BCR|October 6, 2012
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomesAmy R Peck, Agnieszka K Witkiewicz, Chengbao Liu, et al.
The American Journal of Pathology|May 11, 2013
STAT5A/B gene locus undergoes amplification during human prostate cancer progressionBassem R Haddad, Lei Gu, Tuomas Mirtti, et al.
The American Journal of Pathology|January 24, 2009
Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formationFederica Sotgia, Mathew C Casimiro, Gloria Bonuccelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 SignalingThai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Clinical Breast Cancer|January 17, 2025
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast CancerSailaja Kamaraju, Amy M Fowler, Sergey Tarima, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Oncotarget|November 16, 2017
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growthTimothy G Pestell, Xuanmao Jiao, Mukesh Kumar, et al.
Science Advances|September 15, 2021
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancersYunguang Sun, Ning Yang, Fransiscus E Utama, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Breast Cancer Research and Treatment|July 17, 2023
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapyLubna N Chaudhary, Julie M Jorns, Yunguang Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failureAmy R Peck, Agnieszka K Witkiewicz, Chengbao Liu, et al.
Breast Cancer Research : BCR|October 6, 2012
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomesAmy R Peck, Agnieszka K Witkiewicz, Chengbao Liu, et al.
The American Journal of Pathology|May 11, 2013
STAT5A/B gene locus undergoes amplification during human prostate cancer progressionBassem R Haddad, Lei Gu, Tuomas Mirtti, et al.
The American Journal of Pathology|January 24, 2009
Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formationFederica Sotgia, Mathew C Casimiro, Gloria Bonuccelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 SignalingThai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Clinical Breast Cancer|January 17, 2025
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast CancerSailaja Kamaraju, Amy M Fowler, Sergey Tarima, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Oncotarget|November 16, 2017
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growthTimothy G Pestell, Xuanmao Jiao, Mukesh Kumar, et al.
Science Advances|September 15, 2021
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancersYunguang Sun, Ning Yang, Fransiscus E Utama, et al.
Pageof 14